Clinical Efficacy Observation of Amlodipine Combined with Atorvastatin in the Treatment of Elderly Pa-tients with Acute Cerebral Infarction Hypertension
- VernacularTitle:氨氯地平联合阿托伐他汀治疗老年急性脑梗死高血压的疗效观察
- Author:
Waner WU
;
Chunxia ZHOU
;
Yang FANG
;
Jun WANG
- Publication Type:Journal Article
- Keywords:
Amlodipine;
Atorvastatin;
Acute cerebral infarction hypertension
- From:
China Pharmacist
2014;(12):2075-2077
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To discuss the effect of amlodipine combined with atorvastatin in the treatment of elderly patients with acute cerebral infarction hypertension. Methods:Totally 86 cases with acute cerebral infarction hypertension were randomly divided into the treatment group (43 cases) and the control group (43 cases). The control group received amlodipine 5mg, po, qd, and the treatment group was given atorvastatin 20mg additionally, po, qd. After the one-month treatment, the efficacy of the two groups was studied and compared, and the changes in neural function defect scale, blood pressure, blood lipids and CRP were also investigated. Results:Af-ter the treatment, the total effective rate and the total effective rate of antihypertensive effect in the treatment group were both signifi-cantly higher than those in the control group (P<0. 05). The neurological deficit scores of the two groups were significantly higher than those before the treatment (P<0. 05), and those of the observation group was significantly higher than those of the control group (P<0. 05). The blood pressure of the two groups was both decreased after the treatment(P<0. 05), and the decrease in the treat-ment group was more significant (P<0. 05). TC, TG, LDL-C and CRP levels of the two groups had significant decrease after the treatment (P>0. 05), and those in the treatment group was significant lower than those in the control group (P<0. 05). Conclu-sion:Amlodipine combined atorvastatin in the treatment of elderly patients with acute cerebral infarction hypertension shows significant effect with low incidence of adverse drug reaction, which is worthy of wider application.
